Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W8FE
|
|||
| Former ID |
DNCL002689
|
|||
| Drug Name |
CV-301
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 2 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [2] | ||
| Diabetic neuropathy [ICD-11: 8C0Z] | Phase 2 | [2] | ||
| Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 2 | [1], [3], [4] | ||
| Company |
BN ImmunoTherapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019475) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.